About us Contacts Drug interactions: 390 212
Drug search by name

Eskalith-CR and Pristiq

Determining the interaction of Eskalith-CR and Pristiq and the possibility of their joint administration.

Check result:
Eskalith-CR <> Pristiq
Relevance: 09.11.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Talk to your doctor before using lithium together with desvenlafaxine. Combining these medications can increase the risk of a rare but serious condition called the serotonin syndrome, which may include symptoms such as confusion, hallucination, seizure, extreme changes in blood pressure, increased heart rate, fever, excessive sweating, shivering or shaking, blurred vision, muscle spasm or stiffness, tremor, incoordination, stomach cramp, nausea, vomiting, and diarrhea. Severe cases may result in coma and even death. You should contact your doctor immediately if you experience these symptoms while taking the medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: Lithium may enhance the pharmacologic effects of serotonin reuptake inhibitors (e.g., SSRIs, SNRIs, nefazodone, trazodone) and potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. The exact mechanism by which lithium increases serotonergic activity is unknown. The interaction has been reported with selective serotonin reuptake inhibitors including fluoxetine and fluvoxamine and the serotonin-norepinephrine reuptake inhibitor venlafaxine. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.

MANAGEMENT: Caution is advised if lithium is prescribed in combination with serotonin reuptake inhibitors. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is generally recommended following use of fluoxetine before administering another serotonergic agent. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.

References
  • Bijl D "The serotonin syndrome." Neth J Med 62 (2004): 309-13
  • Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
  • Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7
  • Noveske FG, Hahn KR, Flynn RJ "Possible toxicity of combined fluoxetine and lithium." Am J Psychiatry 146 (1989): 1515
  • Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
  • Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
  • "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.
  • "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  • "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.
  • "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.
  • Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5
  • Muly EC, McDonald W, Steffens D, Book S "Serotonin syndrome produced by a combination of fluoxetine and lithium." Am J Psychiatry 150 (1993): 1565
  • Hadley A, Cason MP "Mania resulting from lithium-fluoxetine combination." Am J Psychiatry 146 (1989): 1637-8
  • "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.
  • "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.
  • Sobanski T, Bagli M, Laux G, Rao ML "Serotonin syndrome after lithium add-on medication to paroxetine." Pharmacopsychiatry 30 (1997): 106-7
  • "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.
Eskalith-CR

Generic Name: lithium

Brand name: Eskalith, Lithobid, Lithonate, Lithotabs, Eskalith-CR

Synonyms: Eskalith-CR (Oral)

Pristiq

Generic Name: desvenlafaxine

Brand name: Khedezla, Pristiq

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction